NME1 Antibody
Nucleoside diphosphate kinase A, NDP kinase A, NDK A, Tumor metastatic process-associated protein, Metastasis inhibition factor nm23, nm23-H1, Granzyme A-activated DNase, GAAD, NME1, NDPKA, NM23, NB, AWD, NBS, NDPK-A.
Description
Product Specs
Nucleoside diphosphate kinase (NDK), composed of 'A' (encoded by NME1) and 'B' (encoded by NME2) isoforms and forming a hexamer, plays a role in cell proliferation, differentiation, development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. NME1 is known to suppress tumor metastasis and is crucial for the synthesis of nucleoside triphosphates, excluding ATP. It is essential for neural development, particularly neural patterning and cell fate determination. Notably, NME1 gene expression varies across tumor types, with its levels linked to both reduced and increased metastatic potential. A decrease in NME1 expression is associated with aggressive behavior in melanoma, breast, colon, and gastric carcinomas. Conversely, elevated NME1 expression is observed in advanced thyroid carcinomas. Somatic mutations in the NME1 gene are found in neuroblastoma, where increased NME1 levels are correlated with aggressive tumor characteristics.
The solution contains 1mg/ml of the antibody in a buffer of PBS at pH 7.4, supplemented with 10% glycerol and 0.02% sodium azide.
This NME1 antibody has undergone testing in various applications, including ELISA, Western blot analysis, Flow cytometry, and ICC/IF, to confirm its specificity and reactivity. However, it's important to note that optimal working dilutions may vary depending on the specific application and should be determined through titration.
Nucleoside diphosphate kinase A, NDP kinase A, NDK A, Tumor metastatic process-associated protein, Metastasis inhibition factor nm23, nm23-H1, Granzyme A-activated DNase, GAAD, NME1, NDPKA, NM23, NB, AWD, NBS, NDPK-A.
NME1 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
PAT5F4AT.
Anti-human NME1 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human NME1 amino acids 1-152 purified from E. coli.
Mouse IgG2b heavy chain and k light chain.
Product Science Overview
Non-Metastatic Cells 1 (NME1), also known as NM23-H1, is a gene that encodes a protein involved in various cellular processes, including cell proliferation, differentiation, and apoptosis. The study of NME1 has gained significant attention due to its role in suppressing metastasis in cancer cells. The use of mouse anti-human antibodies targeting NME1 has been instrumental in advancing our understanding of its function and potential therapeutic applications.
NME1 was first identified in the early 1990s as a gene associated with reduced metastatic potential in melanoma cells. Subsequent studies revealed that NME1 is a member of the nucleoside diphosphate kinase (NDPK) family, which plays a crucial role in maintaining cellular energy homeostasis by catalyzing the transfer of phosphate groups from nucleoside triphosphates to nucleoside diphosphates.
NME1 is involved in several critical cellular functions:
- Cell Proliferation and Differentiation: NME1 regulates cell cycle progression and differentiation by modulating the activity of various signaling pathways.
- Apoptosis: NME1 has been shown to promote apoptosis in response to cellular stress, thereby preventing the survival and proliferation of damaged cells.
- DNA Repair: NME1 is involved in DNA repair mechanisms, ensuring genomic stability and preventing mutations that could lead to cancer development.
NME1 is ubiquitously expressed in various tissues, with higher expression levels observed in tissues with high proliferative capacity, such as the liver, spleen, and thymus. In cancer, NME1 expression is often downregulated in metastatic cells compared to non-metastatic cells, highlighting its role as a metastasis suppressor.
The expression and activity of NME1 are tightly regulated by multiple mechanisms:
- Transcriptional Regulation: Various transcription factors, including p53 and c-Myc, regulate the expression of NME1 in response to cellular signals.
- Post-Translational Modifications: NME1 undergoes several post-translational modifications, such as phosphorylation and acetylation, which modulate its activity and stability.
- Protein-Protein Interactions: NME1 interacts with various proteins, including those involved in signal transduction and cytoskeletal organization, to exert its biological functions.
The use of mouse anti-human NME1 antibodies has provided valuable insights into the therapeutic potential of targeting NME1 in cancer treatment. These antibodies have been used in various experimental models to study the effects of NME1 modulation on tumor growth and metastasis. The findings suggest that enhancing NME1 activity or expression could be a promising strategy for preventing cancer metastasis and improving patient outcomes.
